Pascal Soriot, AstraZeneca CEO (AP Images)

#ACC21: As­traZeneca's Farx­i­ga missed big on Covid-19 study, but it's tak­ing SGLT2 safe­ty da­ta as a sil­ver lin­ing

As­traZeneca hasn’t seen many set­backs in re­cent months for SGLT2 in­hibitor Farx­i­ga, which broke ground in heart fail­ure and kid­ney dis­ease re­gard­less of di­a­betes di­ag­no­sis. But the British drug­mak­er had to ad­mit de­feat in tak­ing Farx­i­ga in­to Covid-19. How­ev­er, fol­low-up re­sults add a bit of a sil­ver lin­ing to that tri­al’s safe­ty da­ta.

Of hos­pi­tal­ized Covid-19 pa­tients dosed with As­traZeneca’s Farx­i­ga, 11.2% ex­pe­ri­enced an or­gan fail­ure or died af­ter 30 days of ther­a­py com­pared with 13.8% of those giv­en place­bo, ac­cord­ing to fol­low-up da­ta from the DARE-19 study re­vealed Sun­day at the vir­tu­al Amer­i­can Col­lege of Car­di­ol­o­gy meet­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.